CRISPR Therapeutics (NASDAQ:CRSP Get Rating) and Inhibrx (NASDAQ:INBX Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Earnings and Valuation

This table compares CRISPR Therapeutics and Inhibrxs revenue, earnings per share and valuation.

Profitability

This table compares CRISPR Therapeutics and Inhibrxs net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CRISPR Therapeutics and Inhibrx, as reported by MarketBeat.

CRISPR Therapeutics presently has a consensus price target of $114.71, indicating a potential upside of 70.25%. Inhibrx has a consensus price target of $44.33, indicating a potential upside of 291.64%. Given Inhibrxs stronger consensus rating and higher possible upside, analysts plainly believe Inhibrx is more favorable than CRISPR Therapeutics.

Insider & Institutional Ownership

56.1% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 59.6% of Inhibrx shares are owned by institutional investors. 10.7% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 25.8% of Inhibrx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

CRISPR Therapeutics has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Comparatively, Inhibrx has a beta of 3.1, suggesting that its stock price is 210% more volatile than the S&P 500.

Summary

CRISPR Therapeutics beats Inhibrx on 8 of the 14 factors compared between the two stocks.

About CRISPR Therapeutics (Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

About Inhibrx (Get Rating)

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

More here:
Analyzing CRISPR Therapeutics (NASDAQ:CRSP) and Inhibrx (NASDAQ:INBX) - Defense World

Comments are closed.